Suggested remit: To appraise the clinical and cost effectiveness of daprodustat within its marketing authorisation for treating anaemia in adults with chronic kidney disease.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 3987

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
28 January 2022 - 25 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual